Novo CSO is pleased with product, disappointed by delay
Science chief Mads Krogsgaard Thomsen believes Novo Nordisk will hold a very strong competitive position on the European market for drugs to treat bleeding disorders following submission of an application for the drug N9-GP - but he laments the late submission.
BY STEFAN SINGH KAILAY
Chief Scientific Officer Mads Krogsgaard Thomsen is always pleased when the organization he heads performs clinical work that ultimately leads to a marketing application with one of the major approval agencies across the world. That is also the feeling he is left with Thursday as Novo Nordisk submitted an application for long-acting factor IX drug N9-GP to treat haemophilia B, but he does feel a sting of disappointment.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo spends 1.5 billion on new factory
For abonnenter
Analyst: This will be crucial to Novo’s haemophilia drug
For abonnenter
